University of Massachusetts Medical School
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of Massachusetts Medical School
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.
Sanofi says the virtual innovation lab it will create with Google will enable precision health care and optimize R&D and commercial operations. Incoming CEO Hudson has been tasked with improving the pharma’s R&D and digital capabilities.
The start-up incubated by Atlas Venture is focused on the delivery of nucleic acids and other molecules to skeletal, cardiac and smooth muscles. The Series A round will allow Dyne to take its lead program for myotonic dystrophy type 1 (DM1) into the clinic.
- Academic and Research Institutions
- Other Names / Subsidiaries
- University of Massachusetts